ATE277639T1 - Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten - Google Patents

Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten

Info

Publication number
ATE277639T1
ATE277639T1 AT00985643T AT00985643T ATE277639T1 AT E277639 T1 ATE277639 T1 AT E277639T1 AT 00985643 T AT00985643 T AT 00985643T AT 00985643 T AT00985643 T AT 00985643T AT E277639 T1 ATE277639 T1 AT E277639T1
Authority
AT
Austria
Prior art keywords
agonists
adenosine
compositions
solvate
acceptable salt
Prior art date
Application number
AT00985643T
Other languages
English (en)
Inventor
Charanjit Bountra
Nicholas Maughan Clayton
Wood Road Gunnels
Alan Naylor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE277639T1 publication Critical patent/ATE277639T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00985643T 1999-12-20 2000-12-19 Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten ATE277639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930077.4A GB9930077D0 (en) 1999-12-20 1999-12-20 Medicaments
PCT/GB2000/004902 WO2001045685A2 (en) 1999-12-20 2000-12-19 Formulations of adenosine a1 agonists

Publications (1)

Publication Number Publication Date
ATE277639T1 true ATE277639T1 (de) 2004-10-15

Family

ID=10866661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985643T ATE277639T1 (de) 1999-12-20 2000-12-19 Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten

Country Status (8)

Country Link
US (1) US20030018008A1 (de)
EP (1) EP1239882B1 (de)
JP (1) JP2003518043A (de)
AT (1) ATE277639T1 (de)
AU (1) AU2204701A (de)
DE (1) DE60014429D1 (de)
GB (1) GB9930077D0 (de)
WO (1) WO2001045685A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
WO2001087305A2 (en) * 2000-05-18 2001-11-22 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
US20050222178A1 (en) * 2002-06-17 2005-10-06 Mark Shipton Process
JPWO2005099698A1 (ja) * 2004-04-15 2008-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化された４−アミノ−５−クロロ−Ｎ−［（１Ｒ，３ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタ−３−イル］−２−［１−メチルブタ−２−インイルオキシ］ベンズアミド含有組成物
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
WO1998019674A2 (en) * 1996-11-05 1998-05-14 Head Explorer Aps A method for treating tension-type headache
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia

Also Published As

Publication number Publication date
JP2003518043A (ja) 2003-06-03
DE60014429D1 (de) 2004-11-04
WO2001045685A3 (en) 2002-02-28
GB9930077D0 (en) 2000-02-09
WO2001045685A2 (en) 2001-06-28
AU2204701A (en) 2001-07-03
US20030018008A1 (en) 2003-01-23
EP1239882A2 (de) 2002-09-18
EP1239882B1 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
BR0013905A (pt) Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
DE60042828D1 (de) Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
TR200101633T2 (tr) Farmasötik bileşim
BR0015821A (pt) Derivados de pirimidina
WO2001045684A3 (en) Formulations of adenosine a1 agonists
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BR0211938A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do dito composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo, e, método para tratar os distúrbios de fertilidade em pacientes em necessidade do mesmo
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
ATE342734T1 (de) Adenosin a1 antagonisten gegen männliche sterilität
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties